Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Counterpoint

Management of invasive mold infections in patients with prolonged neutropenia and hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) has been hampered by the difficulty in diagnosing these infections. Definite diagnosis invariably centers on histologic identification of hyphae in tissue or on culture from a sterile body site. Therefore, most practitioners have relied on prophylaxis and empiric therapy. Currently, emphasis is shifting from routine prophylaxis and empiric therapy to screening of patients with neutropenia at high risk so that clinicians can administer appropriate antifungal therapy early, when it can potentially improve patient outcome. Non–culture-based microbiologic tools are at the forefront of this paradigm shift. Commercially available methods to detect fungal antigens and sophisticated techniques to detect fungal DNA may be used as screening tools during the highest risk period. Together with assessment of clinical signs, cultures, and especially CT scanning, these methods are useful for starting antifungal therapy preemptively. While awaiting further evaluation of these tools during the postengraftment period of allogeneic HSCT, mold-active prophylaxis targeting the subgroup of patients with severe acute or chronic GVHD may be justified. However, some critical issues have not yet been adequately addressed, including the generalizability of study results, impact of mucositis and gastrointestinal GVHD on drug bioavailability, need for therapeutic drug monitoring, impact of prophylaxis on the performance of diagnostic assays, and optimal treatment of breakthrough invasive fungal infections.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Johan Maertens, MD, University Hospital Gasthuisberg, Department of Hematology, Acute Leukemia and Hematopoietic Stem Cell Transplantation Unit, Herestraat 49, B-3000, Leuven, Belgium. E-mail: johan.maertens@uz.kuleuven.ac.be
  • 1.

    GoodmanJLWinstonDJGreenfieldRA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med1992;326:845851.

    • Search Google Scholar
    • Export Citation
  • 2.

    SlavinMAOsborneBAdamsR. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized double blind study. J Infect Dis1995;171:15451552.

    • Search Google Scholar
    • Export Citation
  • 3.

    CornelyOAUllmannAJKarthausM. Evidence-based assessment of primary antifungal prophylaxis in patients with haematological malignancies. Blood2003;101:33653372.

    • Search Google Scholar
    • Export Citation
  • 4.

    BowEJLaverdiereMLussierN. Antifungal prophylaxis for severely neutropenic chemotherapy patients. A meta-analysis of randomized-controlled clinical trials. Cancer2002;94:32303246.

    • Search Google Scholar
    • Export Citation
  • 5.

    GlasmacherAPrenticeAGorschluterM. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol2003;21:46154626.

    • Search Google Scholar
    • Export Citation
  • 6.

    VardakasKZMichalopoulosAFalagasME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol2005;131:2228.

    • Search Google Scholar
    • Export Citation
  • 7.

    CornelyOAMaertensJWinstonDJ. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med2007;356:348359.

    • Search Google Scholar
    • Export Citation
  • 8.

    UllmannAJLiptonJHVesoleDH. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med2007;356:335347.

    • Search Google Scholar
    • Export Citation
  • 9.

    MaertensJDeerenDDierickxDTheunissenK. Pre-emptive antifungal therapy: still a way to go. Curr Opin Infect Dis2006;19:551556.

  • 10.

    Mennink-KerstenMADonnellyJPVerweijPE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis2004;4:349357.

    • Search Google Scholar
    • Export Citation
  • 11.

    MaertensJVerhaegenJLagrouK. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood2001;97:16041610.

    • Search Google Scholar
    • Export Citation
  • 12.

    PaganoLCairaMPicardiM. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality—SEIFEM-C Report. Clin Infect Dis2007;44:15241525.

    • Search Google Scholar
    • Export Citation
  • 13.

    UptonAKirbyKACarpenterP. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis2007;44:531540.

    • Search Google Scholar
    • Export Citation
  • 14.

    MaertensJVan EldereJVerhaegenJ. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis2002;186:12971306.

    • Search Google Scholar
    • Export Citation
  • 15.

    OdabasiZMattiuzziGEsteyE. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff, development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis2004;39:199205.

    • Search Google Scholar
    • Export Citation
  • 16.

    MarrKABalajeeSAMcLaughlinL. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis2004;190:641649.

    • Search Google Scholar
    • Export Citation
  • 17.

    MaertensJTheunissenKLodewyckT. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses2007;50:217.

    • Search Google Scholar
    • Export Citation
  • 18.

    MaertensJAKlontRMassonC. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis2007;44:13291336.

    • Search Google Scholar
    • Export Citation
  • 19.

    AsciogluSRexJHDe PauwB. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis2002;34:714.

    • Search Google Scholar
    • Export Citation
  • 20.

    PfeifferCDFineJPSafdarN. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis2006;42:14171427.

    • Search Google Scholar
    • Export Citation
  • 21.

    MaertensJTheunissenKDeerenD. Defining a case of invasive aspergillosis by serum galactomannan. Med Mycol2006;44:S173178.

  • 22.

    ViscoliCMachettiMCappellanoP. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis2004;38:913916.

    • Search Google Scholar
    • Export Citation
  • 23.

    SurmontIStockmanW. Gluconate-containing intravenous solutions: another cause of false-positive galactomannan assay reactivity. J Clin Microbiol2007;45:1373.

    • Search Google Scholar
    • Export Citation
  • 24.

    UptonALeisenringWMarrK. (1→3) beta-D-Glucan assay in the diagnosis of invasive fungal infections. Clin Infect Dis2006;42:10541056.

    • Search Google Scholar
    • Export Citation
  • 25.

    Mennink-KerstenMWarrisAVerweijP. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med2006;354:28342835.

    • Search Google Scholar
    • Export Citation
  • 26.

    WhitePLLintonCJPerryMD. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis2006;42:479486.

    • Search Google Scholar
    • Export Citation
  • 27.

    DenningDWKibblerCCBarnes. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis2003;3:230240.

    • Search Google Scholar
    • Export Citation
  • 28.

    CaillotDCasasnovasOBernardA. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol1997;15:139147.

    • Search Google Scholar
    • Export Citation
  • 29.

    CaillotDCouaillierJFBernardA. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol2001;19:253259.

    • Search Google Scholar
    • Export Citation
  • 30.

    GreeneRESchlammHTOestmannJW. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis2007;44:373379.

    • Search Google Scholar
    • Export Citation
  • 31.

    GreeneR. The radiological spectrum of pulmonary aspergillosis. Med Mycol2005;43(Suppl 1):S147154.

  • 32.

    SegalBHAlmyroudisNGBattiwallaM. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis2007;44:402409.

    • Search Google Scholar
    • Export Citation
  • 33.

    CordonnierCRibaudPHerbrechtR. Société Française de Greffe de Moelle et de Thérapie Cellulaire. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis2006;42:955963.

    • Search Google Scholar
    • Export Citation
  • 34.

    RexJHAnaissieEJBoutatiE. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults. Leukemia2002;16:11971199.

    • Search Google Scholar
    • Export Citation
  • 35.

    JantunenENihtinenAVolinL. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. Bone Marrow Transplant2004;34:891895.

    • Search Google Scholar
    • Export Citation
  • 36.

    ChamilosGMaromEMLewisRE. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis2005;41:6066.

    • Search Google Scholar
    • Export Citation
  • 37.

    Lass-FlörlCReschGNachbaurD. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis2007;45:e101104.

    • Search Google Scholar
    • Export Citation
  • 38.

    MaertensJTheunissenKLagrouK. Pre-emptive antifungal therapy in neutropenic onco-hematology patients. J Invasive Fungal Infect2007;1:49.

    • Search Google Scholar
    • Export Citation
  • 39.

    SeverensJLDonnellyJPMeisJF. Two strategies for managing invasive aspergillosis: a decision analysis. Clin Infect Dis1997;25:11481154.

    • Search Google Scholar
    • Export Citation
  • 40.

    MaertensJTheunissenKVerhoefG. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis2005;41:12421250.

    • Search Google Scholar
    • Export Citation
  • 41.

    OshimaKKandaYAsano-MoriY. Presumptive treatment strategy for aspergillosis in allogeneic hematopoietic stem cell transplant recipients. J Antimicrob Chemother2007;60:350355.

    • Search Google Scholar
    • Export Citation
  • 42.

    CordonnierCPautasCMauryS. Empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients: a prospective randomized study. Presented at the 48th Annual Meeting of the American Society of Hematology; Orlando Florida; December 9–12 2006. Abstract 197-II.

    • Search Google Scholar
    • Export Citation
  • 43.

    CornelyOAMaertensJBresnikM. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis2007;44:12891297.

    • Search Google Scholar
    • Export Citation
  • 44.

    MarrKACrippaFLeisenringW. Cyclophosphamide metabolism is affected by azole antifungals. Blood2004;103:15571559.

  • 45.

    PotoskiBABrownJ. The safety of voriconazole. Clin Infect Dis2002;35:12731275.

  • 46.

    ImhofASchaerDJSchanzUSchwarzU. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly2006;136:739742.

    • Search Google Scholar
    • Export Citation
  • 47.

    TrifilioSPennickGPiJ. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer2007;109:15321535.

    • Search Google Scholar
    • Export Citation
  • 48.

    MarrKASeidelKWhiteTC. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis2000;181:309316.

    • Search Google Scholar
    • Export Citation
  • 49.

    LionakisMSLewisRETorresHA. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis2005;52:1520.

    • Search Google Scholar
    • Export Citation
  • 50.

    KontoyiannisDPLionakisMSLewisRE. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis2005;191:13501360.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 329 296 10
PDF Downloads 31 24 0
EPUB Downloads 0 0 0